Clinical Trials
10 trialsNCT06199557 2025-06-29
HUVAMER
Haukeland University Hospital
Phase 1/2 Recruiting
NCT02124174 2021-04-26
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS
Loyola University
Phase 2 Unknown
NCT00414310 2019-05-21
Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00867672 2016-08-31
DECIDER
University Hospital Freiburg
Phase 2 Completed
NCT00175812 2015-06-24
Differentiation Induction in Acute Myelogenous Leukemia
University of Bergen
Phase 1/2 Completed
NCT00995332 2015-06-24
Disease Stabilization in AML by Treatment With ATRA, Valproic Acid and Low-dose Cytarabine
University of Bergen
Phase 1/2 Completed
NCT01369368 2015-06-24
Treatment of Acute Leukemia Relapse After Allotransplantation
University of Bergen
Phase 1/2 Unknown
NCT00079378 2013-09-30
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00382590 2012-08-07
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00326170 2012-06-15
Phase II 5-Azacytidine Plus VPA Plus ATRA
M.D. Anderson Cancer Center
Phase 2 Completed